NCT05683665|Completed
DaTSCAN Brain Scintigraphy and Psychotropic Treatments: Influence on Radiotracer Binding
DAPSYFIX
Loading search results
DAPSYFIX
Sponsor study identifier
observational
300
1 country
1
Study Start
April 1, 2023
Actual (reported)Primary Completion
June 1, 2023
Actual (reported)Study Completion
July 1, 2023
Actual (reported)DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the presynaptic membrane of dopaminergic neurons. This examination is used in clinical routine in patients presenting a parkinsonian syndrome in search of a pre-synaptic dopaminergic denervation pointing to a neurodegenerative origin of this syndrome To date, there is little literature data evaluating the influence of psychotropic treatments frequently used in clinical routine on DaTSCAN™ CT images. Some studies have shown that SSRI (selective serotonin reuptake inhibitor) and SNRI (serotonin and norepinephrine reuptake inhibitor) antidepressants can significantly alter striatal ioflupane uptake ratios (10-20%) with no obvious influence on the visual interpretation of the examination . The objective of this study was to evaluate the influence of the most commonly used psychotropic therapies, sometimes in combination, on DaTSCAN™ CT images with a large population of patients included in clinical routine.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 1, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 5, 2023
Actual (reported)January 13, 2023
Actual (reported)April 1, 2023
Actual (reported)June 1, 2023
Actual (reported)July 1, 2023
Actual (reported)The influence of psychotropic treatments on radiotracer uptake during DaTSCAN™ tomoscintigraphies.
Binding ratios (specific binding ratio) stratum/occipital cortex, caudate nucleus/occipital cortex, putamen/occipital cortex on the left and right and total number of strokes recorded as a function of the presence or absence of psychotropic treatment at the time of examination
1 year
DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the pre-synaptic membrane of dopaminergic neurons
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
All patients routinely referred for SPECT examination assessing the pre-synaptic dopaminergic pathway
CHRU Nancy
Vandœuvre-lès-Nancy, 54511, France
300 participants (actual enrollment reported by the registry).
First Submitted
January 5, 2023
First Posted
January 13, 2023
Study Start
April 1, 2023
Actual (reported)Sleepiness in Parkinson's Patients With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation
Contact the study team to confirm eligibility.
Primary Completion
June 1, 2023
Actual (reported)Study Completion
July 1, 2023
Actual (reported)Last Updated
July 6, 2023
Record last verified: 2023-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: